CD34 Antibody (rHPCA1/8500) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-20978
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Mouse IgG1 Lambda Clone # rHPCA1/8500
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Recombinant fragment (around aa100-300) of human CD34 protein (exact sequence is proprietary)
Localization
Cell surface.
Specificity
Anti-CD34 labels > 85% of angiosarcoma and Kaposi s sarcoma, but with a lower specificity
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 Lambda
Description
Positive Controls: Human tonsil or angiosarcoma.
Antibody with azide - store at 2 to 8C. Non-hazardous. No MSDS required.
Antibody with azide - store at 2 to 8C. Non-hazardous. No MSDS required.
Scientific Data Images for CD34 Antibody (rHPCA1/8500) - BSA Free
CD34 Antibody (rHPCA1/8500)
Formalin-fixed, paraffin-embedded human uterus stained with CD34 antibody (rHPCA1/8500). HIER: Tris/EDTA, pH9.0, 45min. Secondary: HRP-polymer, 30min. DAB, 5min.Applications for CD34 Antibody (rHPCA1/8500) - BSA Free
Application
Recommended Usage
Immunohistochemistry-Paraffin
1-2 ug/ml
Application Notes
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes. at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
Optimal dilution for a specific application should be determined.
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10mM PBS
Format
BSA Free
Preservative
0.05% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: CD34
CD34 has commonly been used as a marker for the diagnosis and classification of various diseases and pathologies including leukemia and solitary fibrous tumor (SFT) (2,5). In terms of immunohistochemistry and histopathology, CD34 has been the most common marker for SFT and is expressed in ~79% of cases (5). In addition to its use as a cell marker, CD34-postive (CD34+) hematopoietic stem cells have been used therapeutically in patients following radiation or chemotherapy due to their regenerative potential (6). There are several clinical trials showing promising results for CD34+ cell therapy for cardiovascular diseases including heart failure, ischemia, dilated cardiomyopathy, acute myocardial infarction, and angina (6). Besides hematopoietic lineages, CD34 is also expressed in non-hematopoietic cells including mesenchymal stem cells, endothelial cells and progenitors, fibrocytes, muscle satellite cells, and some cancer stem cells (1,3). While the clinical and cell therapy applications of CD34 as a cell marker is well documented, the function of CD34 is less understood but has been implicated in many cellular processes such as adhesion, proliferation, signal transduction, differentiation, and progenitor phenotype maintenance (1,3).
References
1. Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S., & Hopkinson, A. (2014). Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem cells (Dayton, Ohio), 32(6), 1380-1389. https://doi.org/10.1002/stem.1661
2. Krause, D. S., Fackler, M. J., Civin, C. I., & May, W. S. (1996). CD34: structure, biology, and clinical utility. Blood, 87(1), 1-13
3. Kapoor, S., Shenoy, S. P., & Bose, B. (2020). CD34 cells in somatic, regenerative and cancer stem cells: Developmental biology, cell therapy, and omics big data perspective. Journal of cellular biochemistry, 121(5-6), 3058-3069. https://doi.org/10.1002/jcb.29571
4. Uniprot (P28906)
5. Davanzo, B., Emerson, R. E., Lisy, M., Koniaris, L. G., & Kays, J. K. (2018). Solitary fibrous tumor. Translational gastroenterology and hepatology, 3, 94. https://doi.org/10.21037/tgh.2018.11.02
6. Prasad, M., Corban, M. T., Henry, T. D., Dietz, A. B., Lerman, L. O., & Lerman, A. (2020). Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular research, 116(8), 1424-1433. https://doi.org/10.1093/cvr/cvaa027
Alternate Names
CD34, HPCA1
Gene Symbol
CD34
Additional CD34 Products
Product Documents for CD34 Antibody (rHPCA1/8500) - BSA Free
Product Specific Notices for CD34 Antibody (rHPCA1/8500) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...